Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 7/20 | 0.48 |
| ▸ | CTSL | P07711 | 10/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CTSH | P09668 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | CTSF | Q9UBX1 | 2/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20397904 | 1.00 | CTSC (0.48) | CTSCCTSLCTSKCYP1A2CYP3A4 | |
| SCHEMBL20397591 | 0.89 | CTSL (0.54) | CTSCCTSLCTSKCYP1A2CYP3A4 | |
| SCHEMBL20397593 | 0.89 | CTSL (0.54) | CTSCCTSLCTSKCYP1A2CYP3A4 | |
| SCHEMBL18262731 | 0.87 | CTSC (0.49) | CTSCCTSLCTSKCYP1A2CYP3A4 | |
| SCHEMBL18262732 | 0.87 | CTSC (0.49) | CTSCCTSLCTSKCYP1A2CYP3A4 | |
| SCHEMBL20415723 | 0.84 | CTSK (0.51) | CTSCCTSLCTSKCTSB | |
| SCHEMBL4425402 | 0.79 | CTSC (0.71) | CTSCCTSLCTSKCYP1A2CYP3A4 | |
| SCHEMBL5906582 | 0.79 | CTSC (0.71) | CTSCCTSLCTSKCYP1A2CYP3A4 | |
| SCHEMBL18262781 | 0.78 | CTSC (0.54) | CTSCCTSLCTSKCYP1A2CYP3A4 | |
| SCHEMBL18262784 | 0.78 | CTSC (0.54) | CTSCCTSLCTSKCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858314-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2020-12-08 | — | — | US | disclosed |
| EP-3303284-B1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN SEIYAKU KK (JP) | 2020-04-08 | — | — | EP | disclosed |
| US-20180208552-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858314-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, SAAL1, FPR2 | CTSC 2272/4885CTSL 157/4885CTSK 2965/4885 |
| US-20180208552-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, SAAL1 | CTSC 2195/4885CTSL 143/4885CTSK 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.